AR069374A2 - Sales de valsartan, proceso para su fabricacion, composiciones farmaceuticas y uso de dichas sales para la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el bloqueo del receptor at1. - Google Patents

Sales de valsartan, proceso para su fabricacion, composiciones farmaceuticas y uso de dichas sales para la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el bloqueo del receptor at1.

Info

Publication number
AR069374A2
AR069374A2 ARP080105034A ARP080105034A AR069374A2 AR 069374 A2 AR069374 A2 AR 069374A2 AR P080105034 A ARP080105034 A AR P080105034A AR P080105034 A ARP080105034 A AR P080105034A AR 069374 A2 AR069374 A2 AR 069374A2
Authority
AR
Argentina
Prior art keywords
salt
bis
valsartan
water
solvent
Prior art date
Application number
ARP080105034A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8169294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR069374(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR069374A2 publication Critical patent/AR069374A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una sal de valsartan, que se selecciona del grupo que consiste en la sal monosodica, la sal monopotásica, la sal disodica, la sal dipotásica, la sal magnésica, la sal cálcica, la sal de bis-dietilamonio, la sal de bis-dipropilamonio, la sal de bis-dibutilamonio, la sal de mono-L-arginina, la sal de bis-L-arginina, la sal de mono-L-lisina, y la sal de bis-L-lisina, así como mezclas de sal de las mismas; proceso para su fabricacion, composiciones farmacéuticas y uso de dichas sales para la preparacion de medicamentos. Reivindicacion 5: La sal de valsartan, caracterizada porque es el tetrahidrato de acuerdo con la reivindicacion 4, identificado por (i) un patron de polvos de rayos X tomado con una cámara Guinier que comprende los siguientes intervalos del plano inter-red: ? in [L]: 16,1+- 0,3, 9,9+- 0,2, 9,4+- 0,2, 7,03+- 0,1, 6,50+- 0,1, 5 5,87+- 0,05, 5,74+- 0,05, 4,95+- 0,05, 4,73+- 0,05, 4,33+- 0,05, 4,15+- 0,05, 4,12+- 0,05, 3,95+- 0,05; o (ii) un espectro de ATR-IR que tiene las siguientes bandas de absorcion expresadas en numeros de onda recíprocos (cm-1); 1621 (f); 1578 (m), 1458 (m); 1441 (m); 1417 (m); 1364 (m), 1012 (m); 758 (m); 738 (m); 696 (m); 666 (m). Reivindicacion 7: La sal de valsartan, caracterizada porque es el hexahidrato de acuerdo con la reivindicacion 6, identificado por: (i) un patron de polvos de rayos X tomados con una cámara Guinier que comprende los siguientes intervalos del plano inter-red: ? in [L]:19,7+- 0,3, 10,11+- 0,2, 9,8+- 0,2, 7,28+- 0,1, 5,81+- 0,05, 5,68+- 0,05, 5,03+- 0,05, 4,88+- 0,05, 4,18+- 0,05, 4,08+- 0,05, 3,46 +- 0,05; o (iii) un espectro de ATR-IR que tiene las siguientes ondas de absorcion expresadas en numeros de ondas recíprocos (cm-1): 3378 (m); 3274 (m); 2956 (m); 1619 (st); 1557 (m); 1464 (m); 1419 (m); 1394 (f); 1374 (m); 1175 (m); 836 (m), 820 (d); 766 (f); 751 (m); 741 (f); 732 (f). Reivindicacion 14: Un proceso para la fabricacion de una sal de acuerdo con la reivindicacion 1, caracterizado porque: (i) se agregan valsartan y la base apropiada a un solvente orgánico que contenga agua, (ii) se concentra el solvente, por ejemplo mediante calentamiento, si es necesario bajo presion reducida, o mediante evaporacion lenta, por ejemplo a temperatura ambiente, (iii) se equilibra el residuo de evaporacion con la cantidad requerida de agua: (a) suspendiendo el residuo de la evaporacion, que convenientemente todavía está tibio, y que todavía contiene algo de agua, en un solvente apropiado, o (b) equilibrando el exceso de agua en el solvente; lo mediante lo cual en a) y b) está presente el agua existente o agregada en una cantidad donde el agua se disuelva en el solvente orgánico y forme una fase adicional; y (iv) se aísla la sal obtenida.
ARP080105034A 2000-07-19 2008-11-19 Sales de valsartan, proceso para su fabricacion, composiciones farmaceuticas y uso de dichas sales para la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el bloqueo del receptor at1. AR069374A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00115556 2000-07-19

Publications (1)

Publication Number Publication Date
AR069374A2 true AR069374A2 (es) 2010-01-20

Family

ID=8169294

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP010103417A AR032758A1 (es) 2000-07-19 2001-07-17 Sales valsartan, un proceso para su fabricacion, composiciones farmaceuticas y el uso de dichas sales para la preparacion de medicamentos
ARP080105034A AR069374A2 (es) 2000-07-19 2008-11-19 Sales de valsartan, proceso para su fabricacion, composiciones farmaceuticas y uso de dichas sales para la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el bloqueo del receptor at1.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP010103417A AR032758A1 (es) 2000-07-19 2001-07-17 Sales valsartan, un proceso para su fabricacion, composiciones farmaceuticas y el uso de dichas sales para la preparacion de medicamentos

Country Status (31)

Country Link
US (5) US20030207930A1 (es)
EP (1) EP1313714B1 (es)
JP (1) JP4102664B2 (es)
KR (1) KR100529658B1 (es)
CN (2) CN1216873C (es)
AR (2) AR032758A1 (es)
AT (1) ATE406355T1 (es)
AU (2) AU2001289672B2 (es)
BR (1) BR0112665A (es)
CA (1) CA2415962C (es)
CY (1) CY1108559T1 (es)
CZ (1) CZ303389B6 (es)
DE (1) DE60135560D1 (es)
DK (1) DK1313714T3 (es)
EC (1) ECSP034436A (es)
ES (1) ES2309090T3 (es)
HK (1) HK1055963A1 (es)
HU (1) HU229280B1 (es)
IL (2) IL153882A0 (es)
MX (1) MXPA03000525A (es)
MY (2) MY152846A (es)
NO (1) NO326504B1 (es)
NZ (1) NZ523557A (es)
PE (1) PE20020613A1 (es)
PL (1) PL205715B1 (es)
PT (1) PT1313714E (es)
RU (1) RU2275363C2 (es)
SI (1) SI1313714T1 (es)
SK (1) SK287558B6 (es)
WO (1) WO2002006253A1 (es)
ZA (1) ZA200300285B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2415962C (en) 2000-07-19 2010-07-06 Novartis Ag Valsartan salts
RU2334513C3 (ru) * 2002-01-17 2017-10-24 Новартис Аг Фармацевтические композиции, включающие валсартан и ингибиторы нейтральной эндопептидазы (nep)
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
US6869970B2 (en) * 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
AU2003223637A1 (en) * 2002-04-15 2003-11-03 Dr. Reddy's Laboratories Limited Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- (2'-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl) amine (valsartan)
PL373202A1 (en) * 2002-05-17 2005-08-22 Novartis Ag Combination of angiotensin ii receptor blocker and beta-blocker for secondary prevention of myocardial infarction
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
CA2486557A1 (en) * 2002-06-13 2003-12-24 Novartis Ag Calcium salts of indole derived statins
GB0222056D0 (en) * 2002-09-23 2002-10-30 Novartis Ag Process for the manufacture of organic compounds
CA2519490A1 (en) * 2003-03-17 2004-09-30 Teva Pharmaceutical Industries Ltd Polymorphis of valsartan
EP1950204A1 (en) 2003-03-17 2008-07-30 Teva Pharmaceutical Industries Ltd. Amorphous form of valsartan
US7199144B2 (en) 2003-04-21 2007-04-03 Teva Pharmaceuticals Industries, Ltd. Process for the preparation of valsartan and intermediates thereof
US20050165075A1 (en) * 2003-03-31 2005-07-28 Hetero Drugs Limited Novel amorphous form of valsartan
WO2004094392A1 (en) 2003-04-21 2004-11-04 Teva Pharmaceutical Industries Ltd. Process for the preparation of valsartan
WO2005049587A1 (en) * 2003-11-21 2005-06-02 Ranbaxy Laboratories Limited Process for preparation of biphenyl tetrazole
WO2006002983A1 (en) * 2004-07-06 2006-01-12 Novartis Ag Combination of organic compounds
EP2033629B1 (en) * 2004-12-24 2012-11-14 Krka Solid pharmaceutical composition comprising valsartan
EP1674080A1 (en) * 2004-12-24 2006-06-28 KRKA, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan
GB0503062D0 (en) * 2005-02-14 2005-03-23 Novartis Ag Combination of organic compounds
EP1896433A4 (en) * 2005-05-25 2010-06-02 Ipca Lab Ltd NOVEL CRYSTALLINE FORMS OF (S) -N- (1-CARBOXY-2-METHYL-PROP-1-YL) -N-PENTANOYL-N- [2 '- (1H-TETRAZOL-5-YL) BI-PHENYL-4 ylmethyl] amine
FR2886642B1 (fr) * 2005-06-06 2008-05-30 Sanofi Aventis Sa Sels alcalino-terreux d'irbesartan et leur preparation
WO2007045663A2 (en) * 2005-10-19 2007-04-26 Novartis Ag Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
RU2459809C2 (ru) * 2005-11-09 2012-08-27 Новартис Аг Фармацевтические комбинации антагониста рецептора ангиотензина и ингибитора nep
WO2007071750A1 (en) * 2005-12-22 2007-06-28 Enantia, S.L. Intermediates and processes for the preparation of valsartan
WO2008035364A2 (en) * 2006-06-23 2008-03-27 Usv Limited Process for the preparation of micronized valsartan
WO2008018843A1 (en) * 2006-08-08 2008-02-14 Ulkar Kimya Sanayi Ve Ticaret As Process for producing useful salts form of biphenyl-tetrazole compounds
WO2008076780A2 (en) * 2006-12-14 2008-06-26 Isp Investments Inc. Amorphous valsartan and the production thereof
JP2010526126A (ja) * 2007-05-07 2010-07-29 シプラ・リミテッド バルサルタンの製造方法
ES2312162T3 (es) * 2007-06-07 2009-02-16 Inke, S.A. Procedimiento para la obtencion de una sal de valsartan util para la preparacion de valsartan.
EP2209786B1 (en) * 2007-10-05 2013-02-27 Verastem, Inc. Pyrimidine substituted purine derivatives
FI3067043T3 (fi) 2007-11-06 2023-03-18 Novartis Ag Angiotensiinireseptoriantagonistin/-salpaajan (arb) ja neutraalin endopeptidaasin (nep) estäjän superrakenteisiin perustuvia farmaseuttisia koostumuksia
WO2009064681A2 (en) 2007-11-12 2009-05-22 Novartis Ag Liquid compositions comprising valsartan
SG187007A1 (en) 2010-08-03 2013-02-28 Novartis Ag Highly crystalline valsartan
WO2012056294A1 (en) 2010-10-29 2012-05-03 Jubilant Life Sciences Ltd. An improved process for the preparation of n-pentanoyl-n-[[2'-(1h-tetrazol-5-yi)[1,1'-biphenyl]-4-yi]methyl]-l-valine
JP5981940B2 (ja) * 2011-01-20 2016-08-31 ジエンス ハンセン ファーマセウティカル カンパニー リミテッド アジルサルタン有機アミン塩、その製造方法及び使用
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
EP2961734B1 (en) 2013-02-28 2018-09-26 Dermira, Inc. Glycopyrrolate salts
WO2017012600A1 (en) 2015-07-20 2017-01-26 Zentiva, K.S. A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
WO2017042700A1 (en) * 2015-09-07 2017-03-16 Sun Pharmaceutical Industries Limited Solid forms of valsartan and sacubitril
CN105541741A (zh) * 2016-01-14 2016-05-04 青岛友诚高新技术有限公司 一种具有治疗冠心病活性的化合物及其制备方法
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
CN106243056A (zh) * 2016-07-29 2016-12-21 陈欣怡 一种缬沙坦的新型固体形式
TWI648267B (zh) * 2016-09-02 2019-01-21 諾瑞特國際藥業股份有限公司 纈沙坦二鈉鹽新晶型
US10745363B2 (en) 2016-09-02 2020-08-18 Nanjing Noratech Pharmaceuticals Co., Ltd Crystal forms of valsartan disodium salt
US10995060B2 (en) 2016-10-28 2021-05-04 Biocon Limited Amorphous Trisodium Sacubitril Valsartan and process for its preparation
WO2018178295A1 (en) 2017-03-31 2018-10-04 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Stable hot-melt extrudate containing valsartan and sacubitril
WO2019008485A1 (en) 2017-07-06 2019-01-10 Mankind Pharma Ltd FIXED DOSE PHARMACEUTICAL COMPOSITION BASED ON VALSARTAN AND SACUBITRIL
PL3658122T3 (pl) 2017-07-28 2021-10-18 Synthon B.V. Kompozycja farmaceutyczna zawierająca sakubitryl i walsartan
US20200276129A1 (en) 2017-10-13 2020-09-03 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Tablet containing valsartan and sacubitril
EP3498698A1 (en) 2017-12-15 2019-06-19 Mankind Pharma Ltd Solid forms of valsartan disodium and process of preparation thereof
CN108794418A (zh) * 2018-09-18 2018-11-13 中国药科大学 一种缬沙坦烟酰胺共无定形物
EP3766484B1 (en) 2019-07-19 2021-08-25 Zentiva, K.S. Solid pharmaceutical dosage form comprising valsartan and sacubitril
WO2021111464A1 (en) * 2019-12-02 2021-06-10 Harman Finochem Limited A process for the preparation of highly pure valsartan

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499017A (en) * 1983-06-06 1985-02-12 Pfizer Inc. Beta-lactamase inhibiting 6-(alkoxyamino-methyl) penicillanic acid 1,1-dioxide and derivatives
PH30484A (en) * 1990-02-19 1997-05-28 Ciba Geigy Acy compounds pharmaceutical composition containing said compound and method of use thereof
JPH05105698A (ja) * 1991-06-13 1993-04-27 Takeda Chem Ind Ltd ホスホン酸誘導体、その製造法および用途
CN1143908A (zh) 1994-03-17 1997-02-26 西巴-盖尔基股份公司 利用哇尔沙通(valsartan)治疗糖尿病型肾病
MX9707683A (es) 1995-04-07 1997-12-31 Novartis Ag Composiciones de combinacion que contienen benazepril o benazeprilat y valsartan.
AU7213296A (en) 1995-10-06 1997-04-30 Ciba-Geigy Ag At1-receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
GT199800126A (es) 1997-08-29 2000-01-29 Terapia de combinacion.
IT1301759B1 (it) * 1998-06-19 2000-07-07 Nicox Sa Sali nitrati di farmaci antiipertensivi
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
CA2415962C (en) 2000-07-19 2010-07-06 Novartis Ag Valsartan salts

Also Published As

Publication number Publication date
CY1108559T1 (el) 2014-04-09
AU8967201A (en) 2002-01-30
JP4102664B2 (ja) 2008-06-18
KR20030015888A (ko) 2003-02-25
US20140073677A1 (en) 2014-03-13
HU229280B1 (en) 2013-10-28
CN1680341A (zh) 2005-10-12
EP1313714B1 (en) 2008-08-27
US20070149587A1 (en) 2007-06-28
CA2415962C (en) 2010-07-06
CN100413852C (zh) 2008-08-27
SI1313714T1 (sl) 2009-02-28
CN1216873C (zh) 2005-08-31
WO2002006253A1 (en) 2002-01-24
EP1313714A1 (en) 2003-05-28
MY152846A (en) 2014-11-28
CN1443176A (zh) 2003-09-17
ES2309090T3 (es) 2008-12-16
PT1313714E (pt) 2008-11-03
MY136446A (en) 2008-10-31
ATE406355T1 (de) 2008-09-15
SK287558B6 (sk) 2011-02-04
PL360737A1 (en) 2004-09-20
IL153882A (en) 2009-09-01
PE20020613A1 (es) 2002-08-07
US8278339B2 (en) 2012-10-02
HK1055963A1 (en) 2004-01-30
DE60135560D1 (de) 2008-10-09
CA2415962A1 (en) 2002-01-24
JP2004504307A (ja) 2004-02-12
KR100529658B1 (ko) 2005-11-21
AR032758A1 (es) 2003-11-26
BR0112665A (pt) 2003-06-24
MXPA03000525A (es) 2003-05-14
NZ523557A (en) 2004-12-24
CZ2003117A3 (cs) 2003-05-14
US9499499B2 (en) 2016-11-22
HUP0300731A3 (en) 2006-05-29
NO20030232L (no) 2003-01-17
ZA200300285B (en) 2004-03-25
IL153882A0 (en) 2003-07-31
HUP0300731A2 (hu) 2003-09-29
US20080293791A1 (en) 2008-11-27
SK552003A3 (en) 2003-07-01
RU2275363C2 (ru) 2006-04-27
DK1313714T3 (da) 2008-12-15
ECSP034436A (es) 2003-03-10
US20120329844A1 (en) 2012-12-27
AU2001289672B2 (en) 2005-12-08
US20030207930A1 (en) 2003-11-06
NO326504B1 (no) 2008-12-15
NO20030232D0 (no) 2003-01-17
CZ303389B6 (cs) 2012-08-29
PL205715B1 (pl) 2010-05-31

Similar Documents

Publication Publication Date Title
AR069374A2 (es) Sales de valsartan, proceso para su fabricacion, composiciones farmaceuticas y uso de dichas sales para la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el bloqueo del receptor at1.
AR068086A2 (es) Polimorfos del compuesto triazolo (4,5-d) pirimidina , una mezcla , proceso para su preparacion , composicion farmaceutica y uso de estos compuestos para la fabricacion de medicamentos
AR009292A1 (es) Derivados del acido arilsulfonilamino hidroxamico, procesos para su preparacion y composiciones farmaceuticas que lo contienen
RU2008100042A (ru) Новое производное кислоты тритерпенового ряда и содержащий его препарат для наружного применения для кожи
ES2186677T3 (es) Derivados de deuteroporfirina sustituidos en las posiciones 3 y 8, agentes farmaceuticos que contienen estos derivados y procedimientos para su preparacion.
SE8802635L (sv) Saltprodukt
KumaráBarui et al. meso-Substituted BODIPY fluorescent probes for cellular bio-imaging and anticancer activity
Adeyemo et al. Coordination-driven self-assembly of ruthenium (II) architectures: synthesis, characterization and cytotoxicity studies
CN104151173B (zh) 一种寡聚苯乙炔化合物及其制备方法和应用
PT828721E (pt) 2-amino-benxoxazinonas para o tratamento de infeccoes virais
CA2404969A1 (en) Removal of chloride from phosphonomethyliminodiacetic acid process
IS7910A (is) Samsett lyf
Parveen et al. Facile template synthesis of water-soluble triazine-based Schiff base ligand bridged-coordination polymers of Co (ii), Ni (ii), and Cu (ii): structure, biomolecular interactions, and cytotoxic activity
CN104151174B (zh) 一种寡聚苯乙炔化合物及其制备方法与应用
Chappelow Jr et al. The Phenylation and Methylation of Alkoxychlorosilanes1
da SM Forezi et al. 2, 3-Dichloro-1, 4-naphthoquinone in organic synthesis: Recent advances
Karimova et al. Synthesis and antioxidant activity of quercetin ethers
AR037527A1 (es) Un proceso para preparar un producto de reaccion de alcaloides que puede ser convertido en una forma soluble en agua, un producto de reaccion obtenido con dicho proceso, una mezcla de estos productos de reaccion, y el uso de los mismos en calidad de farmacos
Cann et al. Rearrangements of a cation of the neopentyl-type containing a diphenyl-phosphinyl substituent
Brandt et al. New monospirocyclic tetrakis (aziridinyl) cyclotriphosphazene derivatives as potential antitumor drugs
US2962519A (en) Phosphates of 2, 3-dimethoxy-5-methyl hydroquinones
Ganin et al. From chains to ladders in co-crystals with 2, 3-thiophene-15-crown-5, 2, 3-naphtho-15-crown-5, and bis-(18-crown-6)-stilbene constructed by weak hydrogen bonding
Norman et al. 37. The reactions of pyrene with free radicals and with sodium
ES2291120B2 (es) Sintesis y utilizacion del complejo ternario cu-fenantrolina-acido iodohipurico y compuestos relacionados como farmacos antitumorales.
RU94035677A (ru) Способ получения хлорангидридов кислот

Legal Events

Date Code Title Description
FA Abandonment or withdrawal